Skip to main content
Premium Trial:

Request an Annual Quote

Novacyt Secures $5.5M Loan

NEW YORK — French diagnostics firm Novacyt said on Wednesday that it has signed an agreement for a €5.0 million ($5.5 million) secured loan.

The loan is being provided by Harbert European Growth Capital (HEGC). Under the terms of the deal, the four-year loan has a fixed 11 percent annual interest rate and HEGC will receive warrants for around 6 million shares of Novacyt, representing 8.5 percent of the principal loan amount.

Novacyt said the money will be used to repay €1.2 million in bonds under a 2016 deal with Kreos Capital; pay the balance of an €800,000 tied to its acquisition of PCR firm Primerdesign; and repay €900,000 in unconverted debt under a convertible bond facility signed with Negma Group. About  €2.0 million will go toward working capital.

"This new financing addresses the working capital constraints and also removes the requirement for further drawdowns of the dilutive Negma convertible bond facility," Novacyt CEO Graham Mullis said in a statement.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.